BR112013004746A2 - "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto." - Google Patents

"composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."

Info

Publication number
BR112013004746A2
BR112013004746A2 BR112013004746A BR112013004746A BR112013004746A2 BR 112013004746 A2 BR112013004746 A2 BR 112013004746A2 BR 112013004746 A BR112013004746 A BR 112013004746A BR 112013004746 A BR112013004746 A BR 112013004746A BR 112013004746 A2 BR112013004746 A2 BR 112013004746A2
Authority
BR
Brazil
Prior art keywords
amyloid production
beta
gamma secretase
compound
alzheimer
Prior art date
Application number
BR112013004746A
Other languages
English (en)
Portuguese (pt)
Inventor
Makoto Kamata
Minoru Nakamura
Takafumi Takai
Tatsuki Koike
Tetsuya Tsukamoto
Yasutaka Hoashi
Yoshihide Tomata
Yuichi Kajita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013004746(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BR112013004746A2 publication Critical patent/BR112013004746A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013004746A 2010-09-02 2011-09-01 "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto." BR112013004746A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
BR112013004746A2 true BR112013004746A2 (pt) 2016-06-07

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004746A BR112013004746A2 (pt) 2010-09-02 2011-09-01 "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."

Country Status (22)

Country Link
US (3) US8901309B2 (https=)
EP (1) EP2611805A1 (https=)
JP (1) JP5871909B2 (https=)
KR (1) KR20130139895A (https=)
CN (1) CN103249733A (https=)
AR (1) AR082865A1 (https=)
AU (1) AU2011296887A1 (https=)
BR (1) BR112013004746A2 (https=)
CA (1) CA2809779A1 (https=)
CL (1) CL2013000575A1 (https=)
DO (1) DOP2013000051A (https=)
EA (1) EA201390333A1 (https=)
EC (1) ECSP13012535A (https=)
MA (1) MA34556B1 (https=)
MX (1) MX2013002511A (https=)
PE (1) PE20131305A1 (https=)
PH (1) PH12013500403A1 (https=)
SG (1) SG187917A1 (https=)
TW (1) TW201213327A (https=)
UY (1) UY33586A (https=)
WO (1) WO2012029991A1 (https=)
ZA (1) ZA201301929B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455380A4 (en) * 2009-07-13 2012-11-28 Takeda Pharmaceutical HETEROCYCLIC COMPOUND AND USE THEREOF
BR112013004746A2 (pt) * 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
JP7000160B2 (ja) * 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
CA3075892C (en) * 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
US11603440B2 (en) * 2019-09-12 2023-03-14 Dupont Electronics, Inc. Polyimide films and electronic devices
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
AU2004282201A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
CA2580119A1 (en) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
CA2636946A1 (en) 2006-01-11 2007-07-19 Merck And Co., Inc. Fused triazole tachykinin receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR059955A1 (es) * 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2119719A1 (en) 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2010098487A1 (en) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
EP2455380A4 (en) * 2009-07-13 2012-11-28 Takeda Pharmaceutical HETEROCYCLIC COMPOUND AND USE THEREOF
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
BR112013004746A2 (pt) * 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."

Also Published As

Publication number Publication date
US20140350260A1 (en) 2014-11-27
US8822699B2 (en) 2014-09-02
CN103249733A (zh) 2013-08-14
AU2011296887A1 (en) 2013-04-11
MX2013002511A (es) 2013-07-29
CL2013000575A1 (es) 2013-08-23
PE20131305A1 (es) 2013-10-31
WO2012029991A1 (en) 2012-03-08
AR082865A1 (es) 2013-01-16
DOP2013000051A (es) 2013-04-30
JP5871909B2 (ja) 2016-03-01
UY33586A (es) 2012-03-30
ECSP13012535A (es) 2013-06-28
TW201213327A (en) 2012-04-01
JP2013536798A (ja) 2013-09-26
SG187917A1 (en) 2013-04-30
ZA201301929B (en) 2013-11-27
KR20130139895A (ko) 2013-12-23
MA34556B1 (fr) 2013-09-02
EA201390333A1 (ru) 2013-08-30
US8901309B2 (en) 2014-12-02
US20130178497A1 (en) 2013-07-11
US20120059030A1 (en) 2012-03-08
CA2809779A1 (en) 2012-03-08
EP2611805A1 (en) 2013-07-10
PH12013500403A1 (en) 2013-03-25

Similar Documents

Publication Publication Date Title
BR112013004746A2 (pt) "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
BR122020016659B8 (pt) moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
BR112012011072A2 (pt) inibidores de n1-pirazolospirocetona acetil-coa carboxilase
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
PH12017501306A1 (en) Inhibitors of histone demethylases
MX378433B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos
BR112012014858A2 (pt) agente antiplaqueta
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201300152A1 (ru) Гетероариламидные производные
BR112012020311A2 (pt) "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto."
WO2012082436A3 (en) Modulators of histone methyltransferase, and methods of use thereof
WO2012075500A3 (en) 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
ECSP099776A (es) Moduladores de la gamma secretasa
MX380715B (es) Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
CR20190244A (es) Agentes control de plaga
ECSP10010496A (es) Derivado heterociclico fusionado y su uso
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
BR112015002821A8 (pt) compostos inibidores de neprilisina, composição farmacêutica e uso dos compostos
IL199972A (en) Tricyclic compounds and their use as modulators of glucocorticoid receptor
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
BR112013028598A2 (pt) método para promover o crescimento de plantas
ECSP099426A (es) Compuestos de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7il para la modulación de la actividad del adrenoreceptor beta2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.